Clinical Trial Update: Renal MRA Crossover Study Comparing Multihance to Another Contrast Agent [Phase 3]

View source ↗

Summary

Phase 3 renal magnetic resonance angiography crossover trial comparing Multihance to another contrast agent has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Steno-occlusive Disease

Drugs mentioned

• MULTIHANCE (Gadobenate dimeglumine)

Snippet

Sponsor: Bracco Diagnostics, Inc | Conditions: Steno-occlusive Disease | Phase 3 | Status: COMPLETED